Moberg Pharma Q2 FY26 operating loss narrows to SEK 4.7 million; net revenue rises to SEK 5.8 million

• Moberg Pharma posted Jan-Jun net revenue of SEK 10.7 million, up from SEK 7.5 million a year earlier.
• Operating loss narrowed to SEK 6.6 million from SEK 13.9 million, while loss for the period improved to SEK 4.5 million from SEK 10.2 million.
• Q2 net revenue rose to SEK 5.8 million from SEK 3.6 million, as operating loss narrowed to SEK 4.7 million from SEK 9.7 million.
• Cash and cash equivalents totaled SEK 212.4 million at period-end, down from SEK 254.7 million.
• Karo Healthcare deal expanded to Australia, New Zealand, South Korea, Taiwan, and China CBEC; first European trademark transitions cleared, with initial deliveries planned around year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moberg Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260812:BIT:6949:0) on August 13, 2026, and is solely responsible for the information contained therein.